Merck: new indication for Keytruda in Europe

(CercleFinance.com) - The European Commission has authorised Merck to market its immunotherapy Keytruda for the treatment of certain endometrial cancers, the US pharmaceutical company announced on Monday.


The green light from Brussels relates specifically to the combination of Keytruda and Lenvima, an oral tyrosine kinase inhibitor developed by Japanese company Eisai.

This is the first time that an immunotherapy combined with a tyrosine kinase inhibitor has been approved in Europe for the treatment of advanced or recurrent forms of this type of cancer.

In phase III trials, this combination therapy reduced the risk of disease progression and death by 44% compared to conventional chemotherapy.


Copyright (c) 2021 CercleFinance.com. All rights reserved.